New pill targets Hard-to-Treat cancers in first human trial
NCT ID NCT06586957
Summary
This is the first study in people to test a new oral medication called NKT3964. The main goals are to find a safe dose and see if the drug shows early signs of shrinking tumors in adults with advanced cancers that have spread and no longer respond to standard treatments. The study will enroll about 150 people with specific types of advanced solid tumors, including certain breast, ovarian, endometrial, gastric, and lung cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Cancer Institute
NOT_YET_RECRUITINGOrlando, Florida, 32804, United States
Contact
-
Augusta University
NOT_YET_RECRUITINGAugusta, Georgia, 30912, United States
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Florida Cancer Specialists & Research Institute
RECRUITINGLake Mary, Florida, 32746, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Intermountain Health
RECRUITINGSalt Lake City, Utah, 84145, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGAustin, Texas, 78758, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sidney Kimmell Cancer Center - Jefferson Health
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact
Contact Phone: •••-•••-••••
-
UCSF
WITHDRAWNSan Francisco, California, 94158, United States
-
UPMC
WITHDRAWNPittsburgh, Pennsylvania, 15213, United States
-
UT Southwestern
NOT_YET_RECRUITINGDallas, Texas, 75235, United States
Contact
-
University of Arkansas Medical School
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California - Los Angeles
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
Contact
-
University of Kansas
WITHDRAWNFairway, Kansas, 66205, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.